{"nctId":"NCT04249583","briefTitle":"Treatment of Moderate to Severe Glabellar Lines","startDateStruct":{"date":"2020-02-10","type":"ACTUAL"},"conditions":["Glabellar Frown Lines"],"count":300,"armGroups":[{"label":"Treatment","type":"EXPERIMENTAL","interventionNames":["Biological: botulinum toxin"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Biological: Placebo"]}],"interventions":[{"name":"botulinum toxin","otherNames":["QM1114-DP"]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Male or female 18 years of age or older.\n2. Moderate to severe GL at maximum frown as assessed by the Investigator.\n3. Moderate to severe GL at maximum frown as assessed by the subject.\n\nExclusion Criteria:\n\n1. Previous use of any Botulinum toxin in facial areas within 9 months prior to study treatment.\n2. Female who is pregnant, breast feeding, or intends to conceive a child during the study.\n3. Known allergy or hypersensitivity to any component of the investigational product (QM1114-DP) or any botulinum toxin serotype.","healthyVolunteers":true,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Subjects With a â‰¥ 2-grade Improvement From Baseline on the Glabellar Lines Investigator and Subject Assessments at Maximum Frown at One Month.","description":"The investigator and subject evaluate the subject's GL severity using a 4-grade scale (0 = none and 3 = severe)","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"165","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Subjects With a 0 or 1 on the Glabellar Lines Investigator Scale at Maximum Frown","description":null,"paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"187","spread":null},{"groupId":"OG001","value":"3","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":5,"n":222},"commonTop":["COVID-19","Headache"]}}}